A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm

References

• Kumar R, Dhaliwal HP, Kukreja RV, Singh BR. The botulinum toxin as a therapeutic agent: molecular structure and mechanism of action in motor and sensory systems. Semin Neurol. February, 2016;36(1):10–19. doi:10.1055/s-0035-1571215.
   PubMed Web of Science ®Google Scholar
• Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. August, 2000;43(2 Pt 1):249–259. doi:10.1067/mjd.2000.105567.
   PubMed Web of Science ®Google Scholar
• Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol. June, 2012;15(3):325–336. doi:10.1016/j.mib.2012.05.012.
   PubMed Web of Science ®Google Scholar
• Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. January–February, 1980;17(1):21–25. doi:10.3928/0191-3913-19800101-06.
   PubMed Web of Science ®Google Scholar
• Broadbent TJ, Wesley RE, Mawn LA. A survey of current blepharospasm treatment patterns among oculoplastic surgeons. Ophthalmic Plast Reconstr Surg. January–February, 2016;32(1):24–27. doi:10.1097/IOP.0000000000000405.
   PubMed Web of Science ®Google Scholar
• Bladen JC, Feldman I, Favor M, Dizon M, Litwin A, Malhotra R. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia. Eye (Lond). March, 2019;33(3):349–352. doi:10.1038/s41433-018-0203-3.
   PubMed Web of Science ®Google Scholar
• Killer HE, Blumer BK, Bähler A. Approach to traumatic sixth nerve palsy with botulinum toxin A. Neuro-Ophthalmology. 1994;14(6):355–358. doi:10.3109/01658109409024062.
   Web of Science ®Google Scholar
• Chaudhry N, Srivastava A, Joshi L. Hemifacial spasm: the past, present and future. J Neurol Sci. September 15, 2015;356(1–2):27–31. doi:10.1016/j.jns.2015.06.032.
   PubMed Web of Science ®Google Scholar
• Foster KA. Overview and history of botulinum neurotoxin clinical exploitation. In: Clinical Applications of Botulinum Neurotoxin. Berlin, Germany: Springer; 2014:1–5.
   Google Scholar
• Monheit GD, Pickett A. AbobotulinumtoxinA: a 25-year history. Aesthet Surg J. May 1, 2017;37(suppl_1):S4–S11. doi:10.1093/asj/sjw284.
   PubMedGoogle Scholar
• Omprakash H, Rajendran S. Botulinum toxin deaths: what is the fact? J Cutan Aesthet Surg. 2008;1(2):95–97. doi:10.4103/0974-2077.44169.
   PubMedGoogle Scholar
• Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. August, 2006;47(8):1253–1284. doi:10.1111/j.1528-1167.2006.00607.x.
   PubMed Web of Science ®Google Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. March, 1994;9(2):213–217. doi:10.1002/mds.870090216.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. September, 1995;45(9):1743–1746. doi:10.1212/WNL.45.9.1743.
   PubMed Web of Science ®Google Scholar
• Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum A toxin. Ophthalmology. December, 1993;100(12):1861–1866. doi:10.1016/S0161-6420(93)31384-9.
   PubMed Web of Science ®Google Scholar
• Lai KK, Kuk AK, Chan E, Ko ST. The good toxin: 10 years of experience with botulinum toxin A in the treatment of benign essential blepharospasm. Eur J Ophthalmol. May, 2020;26:1120672120925630.
   Google Scholar
• Frampton JE, Silberstein S. Onabotulinumtoxin A: a review in the prevention of chronic migraine. Drugs. April, 2018;78(5):589–600. doi:10.1007/s40265-018-0894-6.
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Gregson N, Smith K, Dasgupta P, GKT Botulinum Study Group. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going. Nat Clin Pract Urol. July, 2007;4(7):379–386. doi:10.1038/ncpuro0839.
   PubMedGoogle Scholar
• Jankovic J. Botulinum toxin: state of the art. Mov Disord. August, 2017;32(8):1131–1138. doi:10.1002/mds.27072.
   PubMed Web of Science ®Google Scholar
• Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. April, 2014;42(3):254–261. doi:10.1111/ceo.12165.
   PubMed Web of Science ®Google Scholar
• Levy RL, Berman D, Parikh M, Miller NR. Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology. September, 2006;113(9):1665–1668. doi:10.1016/j.ophtha.2006.03.055.
   PubMed Web of Science ®Google Scholar
• Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2013;7:11–17. Published December 18, 2013. doi:10.2147/CCID.S51938.
   PubMedGoogle Scholar
• Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120(2):275–290. doi:10.1007/s00702-012-0893-9.
   PubMed Web of Science ®Google Scholar
• Dressler D, Hallett M. Immunological aspects of Botox, dysport and myobloc/neurobloc. Eur J Neurol. February, 2006;13(Suppl 1):11–15. doi:10.1111/j.1468-1331.2006.01439.x.
   PubMed Web of Science ®Google Scholar
• Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry. 1998;64(5):577–580. doi:10.1136/jnnp.64.5.577.
   PubMed Web of Science ®Google Scholar
• Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26:e1–e9. doi:10.2165/11599840-000000000-00000.
   PubMedGoogle Scholar
• Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019;11(9):491. Published August 26, 2019. doi:10.3390/toxins11090491.
   Web of Science ®Google Scholar
• Badarny S, Susel Z, Honigman S. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox. Isr Med Assoc J. July, 2008;10(7):520–522.
   PubMed Web of Science ®Google Scholar
• Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol. June, 1992;12(2):121–127. doi:10.3109/01658109209058127.
   PubMedGoogle Scholar
• Vivancos-Matellano F, Rodríguez-Sanz A, Herrero-Infante Y, Mascías-Cadavid J. Efficacy and safety of long-term therapy with type A botulinum toxin in patients with blepharospasm. Neuroophthalmology. November 26, 2018;43(5):277–283. doi:10.1080/01658107.2018.1542009.
   PubMed Web of Science ®Google Scholar
• Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y). 2012;2:tre-02-85-417-1. doi:10.7916/D88W3C1M.
   PubMedGoogle Scholar
• Hornik A, Gruener G, Jay W. Adverse reactions from botulinum toxin administration. Neuro-Ophthalmology. 2010;34:6–13. doi:10.3109/01658100903576334.
   Web of Science ®Google Scholar